Rapport Therapeutics, Inc. (RAPP) Latest Company News

Nov 4, 2026, 12:00 UTC
Rapport Therapeutics, Inc. reported third-quarter 2026 financial results and stated that it had $815.4 million in cash and cash equivalents as of November 3, 2026, with a cash runway through the end of 2029.
Source:
- globenewswire.com
Nov 2, 2026, 12:00 UTC
Rapport Therapeutics closed an offering of $172.5 million aggregate principal amount of 2.25% convertible senior notes due 2032, including full exercise of the underwriters’ over-allotment option.
Source:
- globenewswire.com
Nov 2, 2026, 12:00 UTC
Rapport Therapeutics closed public offerings of 9,761,905 common shares and pre-funded warrants for up to 1,190,476 shares, alongside a concurrent private placement.
Source:
- globenewswire.com
Oct 30, 2026, 21:58 UTC
Rapport Therapeutics entered into indentures for its 2.25% convertible senior notes, which mature on December 1, 2032 and have an initial conversion rate of 37.3483 shares per $1,000 principal amount.
Oct 28, 2026, 10:00 UTC
Rapport Therapeutics announced pricing of a $150.0 million offering of 2.25% convertible senior notes due 2032.
Source:
- globenewswire.com
Oct 28, 2026, 10:00 UTC
Rapport Therapeutics announced pricing of underwritten offerings of approximately $175.0 million of common stock and up to approximately $25.0 million of pre-funded warrants, plus a concurrent private placement of approximately $30.0 million of common stock.
Source:
- globenewswire.com
Oct 27, 2026, 20:32 UTC
Rapport Therapeutics announced public offerings of $200 million of common stock and $150 million principal amount of convertible senior notes due 2032, along with a concurrent private placement of common stock to an investor.
Source:
- globenewswire.com
Oct 20, 2026, 15:38 UTC
Rapport Therapeutics, Inc. shares rose 3.46% to $29.59.
Source:
- s.kabutan.jp
Oct 20, 2026, 10:19 UTC
Rapport Therapeutics, Inc. shares rose as much as 60% in premarket trading.
Source:
- finance.sina.cn
- benzinga.com
Oct 20, 2026, 10:00 UTC
Rapport Therapeutics, Inc. reported positive topline results from its Phase 2 trial of RAP-219 for bipolar mania, meeting the primary and secondary endpoints with placebo-adjusted improvements at Week 3.
Source:
Aug 5, 2026, 00:00 UTC
Rapport Therapeutics reported a net loss of $56.6 million for Q2 2026, compared to a net loss of $26.7 million in Q2 2025, with diluted EPS of -$1.19.

RAPP

Rapport Therapeutics, Inc. reported third-quarter 2026 financial results and stated that it had $815.4 million in cash and cash equivalents as of November 3, 2026, with a cash runway through the end of 2029.

Rapport Therapeutics closed an offering of $172.5 million aggregate principal amount of 2.25% convertible senior notes due 2032, including full exercise of the underwriters’ over-allotment option.

Rapport Therapeutics closed public offerings of 9,761,905 common shares and pre-funded warrants for up to 1,190,476 shares, alongside a concurrent private placement.

Rapport Therapeutics entered into indentures for its 2.25% convertible senior notes, which mature on December 1, 2032 and have an initial conversion rate of 37.3483 shares per $1,000 principal amount.

Rapport Therapeutics announced pricing of a $150.0 million offering of 2.25% convertible senior notes due 2032.

Rapport Therapeutics announced pricing of underwritten offerings of approximately $175.0 million of common stock and up to approximately $25.0 million of pre-funded warrants, plus a concurrent private placement of approximately $30.0 million of common stock.

Rapport Therapeutics announced public offerings of $200 million of common stock and $150 million principal amount of convertible senior notes due 2032, along with a concurrent private placement of common stock to an investor.

Rapport Therapeutics, Inc. shares rose 3.46% to $29.59.

Rapport Therapeutics, Inc. shares rose as much as 60% in premarket trading.

Rapport Therapeutics, Inc. reported positive topline results from its Phase 2 trial of RAP-219 for bipolar mania, meeting the primary and secondary endpoints with placebo-adjusted improvements at Week 3.

Rapport Therapeutics reported a net loss of $56.6 million for Q2 2026, compared to a net loss of $26.7 million in Q2 2025, with diluted EPS of -$1.19.